JP Morgan 2024 – Gene Kinney
Back at JP Morgan 2024, editor-in-chief Jonah Comstock caught up with Gene Kinney, CEO of Prothena, to learn a little bit about his company’s work on diseases caused by misfolded proteins.
This year, they connected again to get an update on Prothena’s phase 3 programme for AL amyloidosis and its various programmes in Alzheimer’s and Parkinson’s, including partnerships with Roche and Novo Nordisk.
They also discuss larger trends in the neurological disease space; among them, the recent shift from symptom-focused to disease-altering treatments and what will happen now that Eisai and Biogen’s Leqembi has proven a success in the market.
Finally, stay tuned for some of Kinney’s thoughts on AI and how it can be used both clinically and operationally in healthcare, as you can see in the video below.